Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gendicine in Advanced Head and Neck Cancer
NCT00894153Phase 4Unknown
- Sponsor
- Shenzhen SiBiono GeneTech
- Start
- May 2009
- Primary completion
- Jun 2012
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rAdp53 in head and neck cancer (HNC) (3 arms), sponsored by Shenzhen SiBiono GeneTech. Primary endpoints: Target Lesion Complete Response Rate at 3 years, Overall Target Lesion Response Rate at 3 years and 2 more. Status: unknown.
02
Drugs
rAdp53
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT00894153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00894153.